Nature Communications (Feb 2016)
Self-renewal of CD133hi cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer
- Pasquale Sansone,
- Claudio Ceccarelli,
- Marjan Berishaj,
- Qing Chang,
- Vinagolu K. Rajasekhar,
- Fabiana Perna,
- Robert L. Bowman,
- Michele Vidone,
- Laura Daly,
- Jennifer Nnoli,
- Donatella Santini,
- Mario Taffurelli,
- Natalie N. C. Shih,
- Michael Feldman,
- Jun J. Mao,
- Christopher Colameco ,
- Jinbo Chen,
- Angela DeMichele,
- Nicola Fabbri,
- John H. Healey,
- Monica Cricca,
- Giuseppe Gasparre,
- David Lyden,
- Massimiliano Bonafé,
- Jacqueline Bromberg
Affiliations
- Pasquale Sansone
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Claudio Ceccarelli
- Department of Experimental, Diagnostic and Specialty Medicine, AlmaMater Studiorum, Universita' di Bologna
- Marjan Berishaj
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Qing Chang
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Vinagolu K. Rajasekhar
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Fabiana Perna
- Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center
- Robert L. Bowman
- Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center
- Michele Vidone
- Department of Medical and Surgical Sciences, AlmaMater Studiorum, Universita' di Bologna
- Laura Daly
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Jennifer Nnoli
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Donatella Santini
- Pathology Unit, Policlinico S.Orsola-Malpighi University Hospital
- Mario Taffurelli
- Department of Medical and Surgical Sciences, AlmaMater Studiorum, Universita' di Bologna
- Natalie N. C. Shih
- Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania
- Michael Feldman
- Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania
- Jun J. Mao
- Department of Biostatistics and Epidemiology, Abramson Cancer Center, University of Pennsylvania
- Christopher Colameco
- Department of Biostatistics and Epidemiology, Abramson Cancer Center, University of Pennsylvania
- Jinbo Chen
- Department of Biostatistics and Epidemiology, Abramson Cancer Center, University of Pennsylvania
- Angela DeMichele
- Department of Biostatistics and Epidemiology, Abramson Cancer Center, University of Pennsylvania
- Nicola Fabbri
- Orthopedics Service, Memorial Sloan Kettering Cancer Center
- John H. Healey
- Orthopedics Service, Memorial Sloan Kettering Cancer Center
- Monica Cricca
- Department of Experimental, Diagnostic and Specialty Medicine, AlmaMater Studiorum, Universita' di Bologna
- Giuseppe Gasparre
- Department of Medical and Surgical Sciences, AlmaMater Studiorum, Universita' di Bologna
- David Lyden
- Department of Pediatrics, Memorial Sloan Kettering Cancer Center
- Massimiliano Bonafé
- Department of Experimental, Diagnostic and Specialty Medicine, AlmaMater Studiorum, Universita' di Bologna
- Jacqueline Bromberg
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- DOI
- https://doi.org/10.1038/ncomms10442
- Journal volume & issue
-
Vol. 7,
no. 1
pp. 1 – 10
Abstract
ER+ breast cancer patients treated with endocrine therapies often acquire resistance and develop metastasis. In this study, the authors demonstrate that endocrine therapies can promote the self-renewal of CD133hi/ERlodrug resistant cells with metastatic potential driven through the IL6-Notch3 axis activation.
